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Abstract
Background: Overexpression of Cyclooxygenase-2 (COX-2) was observed in many types of
cancers, including esophageal squamous cell carcinoma (ESCC). One functional SNP, COX-2 -
1195G/A, has been reported to mediate susceptibility of ESCC in Chinese populations. In our
previous study, the presence of Helicobacter pylori (H. pylori) was found to play a protective role in
development of ESCC. The interaction of COX-2 and H. pylori in gastric cancer was well
investigated. However, literature on their interaction in ESCC risk is scarce. The purpose of this
study was to evaluate the association and interaction between COX-2 single nucleotide
polymorphism (SNP), H. pylori infection and the risk of developing ESCC.
Methods: One hundred and eighty patients with ESCC and 194 controls were enrolled in this
study. Personal data regarding related risk factors, including alcohol consumption, smoking habits
and betel quid chewing, were collected via questionnaire. Genotypes of the COX-2 -1195
polymorphism were determined by PCR-based restriction fragment length polymorphism. H. pylori
seropositivity was defined by immunochromatographic screening test. Data was analyzed by chi-
squared tests and polytomous logistics regression.
Results: In analysis adjusting for the covariates and confounders, H. pylori seropositivity was found
to be inversely association with the ESCC development (adjusted OR: 0.5, 95% CI: 0.3 – 0.9). COX-
2 -1195 AA homozygous was associated with an increased risk of contracting ESCC in comparison
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with the non-AA group, especially among patients with H. pylori seronegative (adjusted OR ratio:
2.9, 95% CI: 1.2 – 7.3). The effect was strengthened among patients with lower third ESCC
(adjusted OR ratio: 6.9, 95% CI 2.1 – 22.5). Besides, H. pylori seropositivity conveyed a notably
inverse effect among patients with COX-2 AA polymorphism (AOR ratio: 0.3, 95% CI: 0.1 – 0.9),
and the effect was observed to be enhanced for the lower third ESCC patients (AOR ratio: 0.09,
95% CI: 0.02 – 0.47, p for multiplicative interaction 0.008)
Conclusion: H. pylori seropositivity is inversely associated with the risk of ESCC in Taiwan, and
COX-2 -1195 polymorphism plays a role in modifying the influence between H. pylori and ESCC,
especially in lower third esophagus.
Background
Esophageal cancer occurs worldwide with a variable geo-
graphic distribution[1] and the incidence is high in cer-
tain parts of China [2,3]. This malignancy has two
histological subtypes: squamous cell carcinoma (ESCC)
and adenocarcinoma. Most of the esophageal cancers are
ESCC, although the incidence of the adenocarcinoma is
increasing in West countries [4,5]. ESCC is one of the
most fatal forms of carcinoma. Because of dissatisfying the
improvements in prognosis, primary prevention and
intervention are important in the control of the disease.
The development of ESCC of the esophagus is a multifac-
tor process associated with a variety of risk factors. Several
environmental factors have been implicated in the patho-
genesis of ESCC, including tobacco smoking, and alcohol
drinking [6-9]. Recent research in Taiwan also mentioned
that betel quid chewing was another important factor in
developing ESCC [10,11]. However, some cases still
developed ESCC without such risk factors, indicating that
there are other risk factors associated with developing
ESCC.
Overexpression of Cyclooxygenase (COX)-2 is observed
in many types of cancers, including ESCC [12-14]. COX-2
is the inducible form of the enzyme for prostanoid syn-
thesis, and the active products, such as prostaglandins and
prostacyclin, have been implicated in carcinogenesis
[15,16]. COX-2 is also involved in many processes funda-
mental to tumor development, such as apoptosis, cell
adhesion, proliferation, invasion, metastasis and angio-
genesis [17-19]. The COX-2 expression can be induced by
variable stimuli, including cytokines and growth factors.
But it is believed that transcription regulation is the major
process in regulating the express of COX-2. Several natu-
rally occurring single nucleotide polymorphism (SNP) in
the COX-2 promoter region were observed and its distri-
bution varied in different ethnics. One functional SNP,
COX-2 -1195G/A, has been reported in Chinese popula-
tions previously and it locates in the core recognition
sequence of c-MYB in the promoter region [20]. c-MYB is
one of the nuclear proteins and it may have the ability to
induce the transcription of COX-2 gene [20,21], and then
to inhibit apoptosis by overexpression of COX-2 [17,21].
The SNP on c-MYB-recognized region can influence the
expression of COX-2 and may play a role in mediating
susceptibility of ESCC [20].
The role of H. pylori in development of ESCC is still puz-
zling. Several studies revealed the positive correlation
between H. pylori infection and ESCC by histological pat-
tern. An investigation from a Swedish population dis-
closed a positive association between ESCC and both H.
pylori Cag-A positive infection and atrophic gastritis[22].
Bahmanyar et al [23] provided another finding that gastric
ulcer patients had an 80% increased risk of ESCC, and
supposed that corpus atrophy may play a role in ESCC eti-
ology. On the contrary, H. pylori infection had also been
mentioned to be associated with a decreased risk of devel-
oping ESCC [24,25]. According to the study from Wu et al
[25], the protective effect of H. pylori infection was
stronger in younger subjects, nonsmokers, nondrinkers
and in the lower third cases of ESCC. This finding pro-
vides a clue that the influence of H. pylori infection in
developing ESCC may vary according to the location in
the esophagus.
Both overexpression of COX-2 and H. pylori infection
were associated with the development of gastric adenocar-
cinoma [26-28]. The presence of H. pylori has also played
a role in induction of expression of COX-2 in stomach
[29-31]. However, the interaction of H. pylori and COX-2
in risk of ESCC has not been well investigated. In the
present study, we conducted an incident case-control
study to evaluate the relationship of SNP in the COX-2
promoter, H. pylori infection, and their interaction in the
risk of developing ESCC.
Methods
Participants
All subjects were consecutively recruited at the Kaohsiung
Medical University Hospital. This study was carried out
according to the principles of the Declaration of Helsinki
and was approved by the Institutional Review Board (IRB)
of Kaohsiung Medical University Hospital (KMUH-IRB-
960114). One hundred and eighty patients of ESCC and
194 controls were enrolled in this study. All patients ofBMC Gastroenterology 2009, 9:37 http://www.biomedcentral.com/1471-230X/9/37
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ESCC were histopathologically confirmed using gastro-
scopic biopsies. Their data were collected within one
month after diagnosis, at the time when they admitted to
hospital for staging or treatment. The controls were
healthy and cancer-free individuals collected during the
same period from the group receiving routine health
examination, including gastroscopy at the same hospital.
They were selected according the frequency matched to
the patients based on age, sex and ethnicity. The exclusion
criteria of both groups included previous cancer history,
previous peptic ulcer history, previous H. pylori eradica-
tion history, and blood transfusion within 6 months.
Informed consent was obtained from each subject, and
personal data regarding demographic characteristics such
as sex, age and related risk factors, including alcohol con-
sumption, smoking habits and betel quid chewing, were
collected via questionnaire from each participant after
interviewing with trained interviewer. Alcoholic drinker
was defined if the subject had drunk wine, beer or distilled
spirits more than once per week for at least 6 months.
Those who had smoked more than 10 cigarettes per week
for at least 6 months were defined as cigarette smokers.
Those who chewed betel quid each week for at least the
same period were defined as betel quid chewers, and we
defined 10 betel quids as one pack.
Location of ESCC
Location of the ESCC was identified by endoscopic find-
ing or by the image of the chest computed tomography if
the esophageal lumen containing ESCC was narrowing.
Lesions were classified according to their location in
upper, middle or lower third esophagus [32]. Upper third
esophagus extended from cricopharnygeal sphincter (15
cm) to the tracheal bifurcation (23 cm). Lower third
esophagus extended from the approximate level of T9 ver-
tebral body (32 cm) to the gastroesophageal junction (40
cm). If the lesion involved more than one region, location
was defined according the high percentage of mass
located.
COX-2 -1195 polymorphism detection
Peripheral blood samples were collected from all patients
and controls. Heparinized whole blood was centrifuged at
2,000 rpm for 10 min to isolate plasma supernatant (for
H. pylori detection, described as below). Genomic DNA
was extracted from remained blood cells using standard
phenol-chloroform method. Genotypes of the COX-2
promoter region containing -1195G → A were deter-
mined by PCR-based restriction fragment length poly-
morphism (PCR-RFLP). The PCR primer pairs used to
amplify the COX-2 promoter region were 5'-CCC TGA
GCA CTA CCC ATG AT-3' (forward) and 5'-GCC CTT CAT
AGG AGA TAC TGG-3' (reverse). PCR was performed at a
25 μL reaction mixture containing 1.5 μl of DNA tem-
plate, 1 unit of Taq DNA polymerase (Promega, Madison,
WI), 0.1 μmol/L of each primer, 0.2 mmol/L of deoxynu-
cleoside triphosphate, 1.5 mmol/L of MgCl2, and 1× reac-
tion buffer. The PCR profile included an initial melting
step of 2 minutes at 95°C, followed by 35 cycles of 30 sec-
onds at 95°C, 30 seconds at 60°C, 45 seconds at 72°C,
and a final elongation step of 5 minutes at 72°C. Restric-
tion enzymes PvuII (New England Biolabs, Beverly, MA)
was used to distinguish -1195G → A genotype. Genotyp-
ing was performed without knowledge of the case or con-
trol status of the subjects.
H. pylori detection
Because of the variable stenotic change of esophagus in
ESCC subjects, we could not well evaluate the H. pylori
infection status by sampling from gastric tissue. So H.
pylori seropositivity was defined according to the existence
of IgG antibody in plasma. The isolated plasma was stored
at -70°C until analyzed. A commercial immunochroma-
tographic screening test (Chimbio H. pylori STAT-PAK,
Chimbio Diagnostic System, Inc., Medford NY) was used
to detect H. pylori antibodies in plasma. The results were
read 10 minutes by two research technicians after the sub-
ject's plasma was placed into the sample well. In accord-
ance with the manufacturer's instructions, the sensitivity
and specificity of the immunochromatographic test were
94% and 98% respectively.
Statistic analysis
Univariate analysis was performed with the chi-squared
tests in order to search for associations between demo-
graphic characteristics and ESCC. The Hardy-Weinberg
equilibrium test was used to assess the discrepancies
between the observed and the expected COX-2 1195G →
A genotype frequencies among control subjects. Because
of two subgroups of ESCC cases were defined (upper two
third and lower third), polytomous logistics regression
was applied in the multivariate analysis to determine the
risk of contracting the two defined cancer groups [33,34].
Estimates were adjusted for covariates and confounders,
including age, gender, educational level and consumption
of tobacco, alcohol and betel quid, in the regression mod-
els. The potential interaction between COX-2 1195G → A
genotype and H. pylori seropositivity in the development
of ESCC was evaluated by fitting a multiplicative model
with cross-product terms representing the interaction.
Two-sided P-values of 0.05 or below were considered sta-
tistically significant. All analyses were conducted using the
statistical packages of Stata[35].
Results
The demographic characteristics and substance use in
both ESCC patients and controls were listed in Table 1.
The majority of ESCC patients were male. Substantial dif-
ferences in the distribution with regard to education level,BMC Gastroenterology 2009, 9:37 http://www.biomedcentral.com/1471-230X/9/37
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tobacco smoking, alcohol drinking and betel quid chew-
ing were found between ESCC and controls. After adjust-
ing for covariates, high education level (>12 years) had a
significantly reduced risk (adjusted odds ratio (AOR): 0.2,
95% CI: 0.1 – 0.6) of developing ESCC. On the contrary,
tobacco smoking, alcohol drinking and betel quid chew-
ing were associated with an increased risk of ESCC devel-
opment, with a clear dose-dependent effect in the latter
two substances.
The protective effect of H. pylori infection on ESCC was
assessed in Table 2. Sixty two of 180 (37%) ESCC patients
and 102 of 194 (53%) controls were H. pylori seropositive.
After controlling for the covariates, H. pylori seropositivity
was found to confer a 0.5-fold risk (95% CI: 0.3 – 0.9) of
developing ESCC. To further evaluate the effect of H. pylori
infection on the ESCC location, ESCC cases were classified
as two subgroups: lower third and upper two thirds. Com-
pared with the controls (53%), the lower third (34%) and
upper two thirds (38%) of ESCC patients had a lower pos-
itive response for H. pylori, showing a possible protective
effect in the risk of developing ESCC.
The distribution of COX-2 -1195 polymorphism both for
the cases and controls was shown in Table 3. The allelic
frequency for -1195G was 0.52 in controls and 0.44 in
ESCC patients. The polymorphic distribution for COX-2 -
1195 gene was found to well comply with the Hardy-
Table 1: Distributions and odds ratios of ESCC associated with selected demographic characteristics and substance uses
Factor/Category Cases Controls
No. (%) No. (%) AOR1 (95% CI)
Total No. 180 194
Anatomic subsite of the esophagus
Upper 1/3 39 (22)
Middle 1/3 83 (46)
Lower 1/3 58 (32)
Age (years)
<50 63 (35) 70 (36) 1.0
51–60 36 (20) 58 (30) 0.7 (0.4 – 1.2)
61–70 45 (25) 36 (18) 1.4 (0.8 – 2.4)
>70 36 (20) 30 (16) 1.3 (0.7 – 2.4)
Gender
Female 5 (3) 7 (4) 1.0
Male 175 (97) 187 (96) 1.3 (0.4 – 4.2)
Ethnicity
Fukienese 138 (77) 152 (78) 1.0
Aborigines 31 (17) 28 (15) 1.2 (0.7 – 2.1)
Others 11 (6) 14 (7) 0.9 (0.4 – 2.0)
Education level (years)
<7 94 (52) 51 (26) 1.0
7–12 77 (43) 86 (44) 0.7 (0.4 – 1.4)
>12 9 (5) 57 (30) 0.2 (0.1 – 0.6)
p for trend 0.001
Tobacco smoking (pack-years)2
No 14 (8) 101 (52) 1.0
1–20 37 (20) 26 (13) 8.7 (3.2 – 23.6)
>20 129 (72) 67 (35) 7.7 (3.4 – 17.7)
p for trend <0.001
Alcohol drinking (drink-years)2
No 36 (20) 130 (67) 1.0
1–40 44 (24) 34 (18) 3.0 (1.4 – 6.4)
>40 100 (56) 30 (15) 7.2 (3.6 – 14.7)
p for trend <0.001
Betel quid chewing (pack-years)2
No 82 (46) 175 (90) 1.0
1–20 26 (15) 7 (4) 3.9 (1.4 – 10.8)
>20 69 (39) 12 (6) 5.6 (2.5 – 12.5)
p for trend <0.001
1 Odds ratios were adjusted for covariates in the table.
2One drink corresponds to 15.75-g of alcohol; one smoked pack and chewed pack correspond to 20-cigarettes and 10-betel quids, respectively.BMC Gastroenterology 2009, 9:37 http://www.biomedcentral.com/1471-230X/9/37
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Weinberg equilibrium among the controls (P > 0.05).
Multivariate polytomous logistic regression analyses
showed that COX-2 -1195AA homozygous was associated
with an increased risk of contracting ESCC (AOR: 2.3,
95% CI: 1.0 – 5.2). Compared with the non-AA subgroup,
a 2.5-fold significantly elevated risk (95% CI: 1.0 – 6.1)
was identified for lower third ESCC patients who carried
the AA homozygote.
To understand the influence of COX-2 polymorphism on
the ESCC risk with regard to the status of H. pylori infec-
tion, we presented effect modification stratification anal-
ysis in Table 4. Among H. pylori seropositive patients, no
significant relationship between COX-2 -1195 genotypes
and ESCC was detected. However, among H. pylori seron-
egative subjects, -1195AA homozygous was found to con-
fer an increased risk in developing ESCC in comparison
with non-AA polymorphisms (AOR ratio: 2.9, 95% CI: 1.2
– 7.3). This effect was strengthened among patients with
lower third ESCC (AOR ratio: 6.9, 95% CI: 2.1 – 22.5).
Alternatively, H. pylori seropositivity conveyed a notably
inverse effect among patients with COX-2 AA polymor-
phism (AOR ratio: 0.3, 95% CI: 0.1 – 0.9). Similarly, such
opposite effect was observed to be enhanced for the lower
third ESCC patients (AOR ratio: 0.09, 95% CI: 0.02 –
0.47). Compared with that for COX-2 non-AA carriers
(AOR ratio 1.0), significantly heterogeneous inverse can-
cer risk for AA carriers was identified at this subsite of
ESCC (p for multiplicative interaction 0.008), though lim-
ited study samples were used to assess the effect.
Discussion
Several studies have suggested the association between
overexpression of COX-2 and ESCC [12-14]. According the
previous study, COX-2 -1195G/A polymorphism, a func-
tional SNP disclosed in Chinese populations, could modi-
fied not only COX-2 mRNA level, but the risk of ESCC[20].
In the present study, we found similar result that COX-2 -
Table 2: Adjusted OR for cancers at upper, middle and lower third of the esophagus associated with seropositivity of H. pylori
H. pylori infection Controls Location of ESCC Total cases
Upper + Middle lower
No.
(%)
No.
(%)
AOR1
(95% CI)
No.
(%)
AOR1
(95% CI)
No.
(%)
AOR1
(95% CI)
Negative 92
(47)
76
(62)
1.0 38
(66)
1.0 114
(63)
1.0
Positive 102
(53)
46
(38)
0.6
(0.3 – 1.1)
20
(34)
0.5
(0.2 – 1.0)
66
(37)
0.5
(0.3 – 0.9)
1 Odds ratios were adjusted for the covariates (age, gender, education level, pack-years of cigarette smoking and of betel quid chewing, and drink-
years of alcohol drinking) listed in Table 1.
Table 3: Adjusted OR for cancers at upper, middle and lower third of the esophagus associated with COX-2 -1195G/A polymorphism.
COX-2 polymorphism Controls Location of ESCC Total cases
Upper + Middle Lower
No.
(%)
No.
(%).
AOR1
(95% CI)
No.
(%).
AOR1
(95% CI)
No.
(%).
AOR1
(95% CI)
GG 50
(26)
23
(19)
1.0 16
(28)
1.0 39
(22)
1.0
AG 103
(53)
59
(48)
1.7
(0.7 – 4.0)
21
(36)
0.9
(0.3 – 2.3)
80
(44)
1.2
(0.6 – 2.4)
AA 41
(21)
40
(33)
2.0
(0.7 – 5.2)
21
(36)
2.3
(0.8 – 6.7)
61
(34)
2.3
(1.0 – 5.2)
p for H-W2 0.471
GG+AG 153
(79)
82
(67)
1.0 37
(64)
1.0 119
(66)
1.0
AA 41
(21)
40
(33)
1.4
(0.7 – 2.9)
21
(36)
2.5
(1.0 – 6.1)
61
(34)
2.0
(1.1 – 3.9)
1 Odds ratios were adjusted for the covariates (age, gender, education level, pack-years of cigarette smoking and of betel quid chewing, and drink-
years of alcohol drinking) listed in Table 1.
2p value for Hardy-Weinberg equilibrium test.BMC Gastroenterology 2009, 9:37 http://www.biomedcentral.com/1471-230X/9/37
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1195AA homozygous, which had higher COX-2 mRNA
level, was related to increased risk of ESCC (AOR: 2.0, 95%
CI: 1.1 – 3.9) compared with non-AA genotype subjects in
multivariate logistic regression analysis. The trend was the
same in the lower third ESCC cases (AOR: 2.5, 95% CI: 1.0
– 6.1). However, the relationship was absent in upper two
third esophageal area. This is consistent with the existing
evidences from Kawabe et al [36] and Sivula et al [37],
which mentioned that high COX-2 expression in ESCC was
found significantly more often in lower parts of the esopha-
gus. These results suggest that the increased risk of ESCC in
the lower third part of the esophagus may be associated
with the COX-2 -1195AA homozygous, which induces
higher COX-2 expression.
In our previous study as Wu et al [25], we mentioned that
subjects with positive H. pylori infection had reduced risk
of developing ESCC. In the present study with newly col-
lected ESCC subjects and controls, we also found the same
effect of H. pylori in ESCC. On the contrary, there are dif-
ferent findings. Bahmanyar et al[23] found that patients
with gastric ulcer history had higher risk of developing
ESCC, with supposed positive H. pylori infection status
and corpus atrophy change via ulcer presentation. We did
not evaluate the association between gastric ulcer and
ESCC because a higher proportion of gastric ulcer was
induced by drugs in Taiwan [38], especially in elderly sub-
jects who were also the high risk group of ESCC by age.
The COX-2 expression induced by H. pylori infection has
been well evaluated in gastric mucosa previously [29,39],
but research about the interaction in esophageal squa-
mous cells is scarce. A study concerning the histological
change of low esophageal mucosa before and after H.
pylori eradication disclosed that COX-2 expression gradu-
ally increased after treatment [40]. This observation sug-
gests that COX-2 expression in low esophageal region is
lower under H. pylori seropositive status. In the present
study, we put the COX-2 -1195G/A polymorphism under
consideration and found that COX-2 -1195AA homozy-
gote in H pylori seronegative status had increased ESCC
risk (AOR ratio: 2.9, 95% CI: 1.2 – 7.3). This effect was
strengthened among subjects with lower third ESCC
(AOR ratio: 6.9, 95% CI 2.1 – 22.5). Furthermore, H.
pylori seropositivity conveyed a notably inverse effect in
ESCC risk (AOR ratio: 0.3, 95% CI: 0.1 – 0.9) in subjects
carrying COX-2 AA genotype. Such opposite effect was
observed to be enhanced for the lower third ESCC
patients (AOR ratio: 0.09, 95% CI: 0.02 – 0.47). However,
such relationship between H. pylori infection and the risk
of ESCC did not persist in COX-2 non-AA genotype. These
findings suggest that the protective effect to lower third
ESCC risk provided by H. pylori seropositivity may be
mediated by influencing COX-2 AA genotype expression.
Our data also indicated the area in which to search for
underlying mechanism.
Table 4: The effect modification between COX-2 -1195G/A polymorphism and seropositivity of H. pylori on the risk of ESCC at lower 
third of the esophagus and all cancers
COX-2 
polymorph
ism
Lower third ESCC cases Total ESCC cases
H. pylori-negative H. pylori-positive H. pylori 
(+) vs. (-) 
OR ratio 
(95% CI)
H. pylori-negative H. pylori-positive H. pylori 
(+) vs. (-) 
OR ratio 
(95% CI)
Cases/
Controls
AOR1 (95% 
CI)
Cases/
Controls
AOR1 
(95% CI)
Cases/
Controls
AOR1 
(95% CI)
Cases/
Controls
AOR1 
(95% CI)
GG+AG 20/72 1.0 17/81 1.0
(0.4 – 2.5)
1.0
(0.4 – 2.5)
73/72 1.0 46/81 0.7
(0.4 – 1.4)
0.7
(0.4 – 1.4)
AA 18/20 6.9
(2.1 – 22.5)
3/21 0.6
(0.1 – 2.8)
0.09
(0.02 – 
0.47)
41/20 2.9
(1.2 – 7.3)
20/21 0.9
(0.4 – 2.1)
0.3
(0.1 – 0.9)
AA vs. 
GG+AG
OR ratio
(95% CI)
6.9
(2.1 – 22.5)
0.6
(0.1 – 2.7)
2.9
(1.2 – 7.3)
1.2
(0.5 to 3.0)
p for 
interaction
2
0.008 0.172
1 Odds ratios were adjusted for the covariates (age, gender, education level, pack-years of cigarette smoking and of betel quid chewing, and drink-
years of alcohol drinking) listed in Table 1.
2Interaction was examined with likelihood ratio test for cross-product terms based on a multiplicative model.BMC Gastroenterology 2009, 9:37 http://www.biomedcentral.com/1471-230X/9/37
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In consideration of the lower third part of the esophagus,
one of the possible changes under chronic H. pylori infec-
tion is the reduced load of esophageal acid. Long-term H.
pylori infection may provoke gastric atrophy, accompany
with hypochlorhydria [41-44], and the prevalence
increased with advancing age [45]. According to the study
from Lurje et al [46], COX-2 mRNA expression is signifi-
cantly increased in acid-exposed compared to non-
exposed squamous epithelium. Another study from Vall-
bohmer et al [47] disclosed that COX-2 gene expression
was increased in the distal esophageal squamous mucosa
of most patients with gastro-esophageal reflux disease,
and the increased COX-2 expression was usually normal-
ized following anti-reflux surgery. These findings provide
a clue that ESCC development in the lower part of the
esophagus may have a similar carcinogenesis pathway as
esophageal adenocarcinoma in consideration of acid
exposure risk. However, further studies are needed to eval-
uate the relationship between acid exposure in squamous
cell epithelium and development of ESCC.
There are some limitations to the present study. Firstly, we
selected controls only from the group receiving health
examination in which gastroscopy was included. Selec-
tion bias resulting from the will of receiving invasive gas-
troscopy might have distorted our findings. However, the
distribution of COX-2 -1195 genotypes in controls still
complies the Hardy-Weinberg equilibrium. In addition,
the H. pylori infection status was determined according to
the result of serologic method. The ESCC location was
determined relying on the image of chest computed tom-
ography in part of ESCC cases. Misclassification happened
in these variables might influence our study results. Fur-
thermore, limited studied samples might lead to a rela-
tively lower statistical power in certain subgroups. On the
other hand, the strength of our study is that previous stud-
ies [11,34,48] for the relationship between habitual sub-
stance use and the risk of ESCC from the same area of
Taiwan provide us adequate information to well design
the questionnaire and to adjust the influence from those
potential confounding factors.
Conclusion
This study provided evidence that both COX-2 -1195G/A
polymorphism and H. pylori infection had influence in
risk of ESCC in Taiwanese population. Subjects carrying
COX-2 -1195 AA homozygote has increased risk of ESCC
in lower third esophagus. The H. pylori seropositivity had
an inverse association in ESCC development, and it was
observed to be enhanced in subgroup of COX-2 -1195AA
genotype, especially when ESCC is located in lower third
esophagus. These findings suggest that COX-2 -1195 pol-
ymorphism plays a role in modifying the inverse associa-
tion between H. pylori infection and risk of ESCC. The
underlying mechanism needs further investigation.
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